Prevalent‐New User Design for Biosimilar Safety Using Saudi Real‐World Data
Pharmacoepidemiology and Drug Safety · 2026-06 · 35 (6)
DOI: 10.1002/pds.70388 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 27.05.2026. Verfasst von Ohoud Almadani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Saudi Food and Drug Authority, Riyadh, Saudi Arabia. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Antirheumatic Agents, Infections. Die Arbeit nennt 51 Literaturangaben.
Abstract (Originalsprache)
Objective
Incidents of infections associated with biosimilar biological disease‐modifying antirheumatic drugs (bDMARDs) have been communicated to the Saudi Food and Drug Authority (SFDA). This study aimed to evaluate the infection risk related to biosimilar bDMARDs and assess the applicability of the prevalent new‐user design within a Saudi cohort.
Methods
Using the Saudi Real‐World Evidence Network (SRWEN), patients aged ≥ 14 years who initiated or switched to biosimilar versus reference bDMARDs between 2016 and 2025 were identified. A prevalent new‐user design that accounted for prior exposure to reference bDMARDs was implemented. Time‐conditional propensity score (TCPS) matching (1:1 and 1:3) balanced baseline covariates. The study outcome was the risk of any infection, identified via ICD‐10 codes in the main analysis, in addition to laboratory results and antimicrobial prescriptions in the sensitivity analyses. Hazard ratios (HRs) were estimated using Cox proportional hazards models with robust sandwich estimators.
Results
Among 5721 patients contributing 59 856 treatment episodes, 2178 were biosimilar initiators and 2909 were switchers (from the reference product). Adalimumab accounted for 69.5% of use. Over a median 1.6‐year follow‐up, infection incidence rates were comparable between reference and biosimilar groups (456.7 vs. 422.0 per 1000 person‐years). Adjusted HRs showed no significant difference in infection risk (HR 0.89; 95% CI 0.57–1.39, p ‐value: 0.61), with consistent findings across sensitivity and disease‐matched analyses where the adjusted HR was 0.87 (95% CI 0.51–1.50, p ‐value: 0.62).
Conclusion
In this real‐world Saudi cohort, no statistically significant difference in infection risk was observed between biosimilar and reference bDMARD. Larger studies and further evaluation of the prevalent new‐user design are needed to enhance post‐marketing biosimilar surveillance in the region.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Saudi Food and Drug Authority, Riyadh, Saudi Arabia.
- Ministry of National Guard-Health Affairs, Riyadh, Saudi Arabia.
- King Abdullah International Medical Research Centre KAIMRC, Riyadh, Saudi Arabia.
- King Saud Bin Abdulaziz University for Health Sciences KSAU-HS, Riyadh, Saudi Arabia.
- College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
ORCID-Profile: Ohoud Almadani
Zitieren
APA
Almadani, O., Alfakhri, A., Asiri, I., Alturaiki, A., Alrashid, A., & Althunian, T. (2026). Prevalent‐New User Design for Biosimilar Safety Using Saudi Real‐World Data. Pharmacoepidemiology and Drug Safety, 35(6). https://doi.org/10.1002/pds.70388
Vancouver
Almadani O, Alfakhri A, Asiri I, Alturaiki A, Alrashid A, Althunian T. Prevalent‐New User Design for Biosimilar Safety Using Saudi Real‐World Data. Pharmacoepidemiology and Drug Safety. 2026;35(6). doi:10.1002/pds.70388
BibTeX
@article{Almadani2026,
author = {Almadani, Ohoud and Alfakhri, Almaha and Asiri, Ibrahim and Alturaiki, Abdulrahman and Alrashid, Abdulrahman and Althunian, Turki},
title = {Prevalent‐New User Design for Biosimilar Safety Using Saudi Real‐World Data},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
volume = {35},
number = {6},
doi = {10.1002/pds.70388}
}
EUVIMED